Jo Shorthouse

1 week ago | insights.citeline.com | Jo Shorthouse

The 360 Degrees Of European Biotech Financing In 2025Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

1 week ago | insights.citeline.com | Jo Shorthouse

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVieFrom chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach. The FDA said dose optimization may be more important for rare diseases because the small patient populations limit the number of possible clinical trials. (Shutterstock)

1 week ago | insights.citeline.com | Jo Shorthouse

From IVF Failure To Fertility Breakthroughs: Freya’s Microbiome MissionNamed after the Norse goddess of fertility, Freya Biosciences is mapping the reproductive microbiome with a host of women's health indications as the final destination.

3 weeks ago | insights.citeline.com | Jo Shorthouse

The pre|CISION Approach: How Avacta Is Making Toxic Cancer Drugs Safe And More EffectiveAvacta's approach to drug delivery is showing how 'masked' chemotherapy can dramatically improve safety profiles while maintaining or enhancing efficacy where it matters most.

3 weeks ago | insights.citeline.com | Jo Shorthouse

Plans For A London Cancer Hub Promises A New Destination For Biotech InnovationPlans have been submitted for a £1bn development in London that can home biotech companies and encourages cross collaboration with the Institute of Cancer Research. In Vivo took an exclusive tour of the UK’s prospective new cancer innovation district. Plans for the £1bn London Cancer Hub Have Been Submitted